The Future of Genomics: Global Surveillance and Capacity Building.
Despite the initial hype, genomic medicines have faced setbacks in the past decade, with safety concerns being a major issue. This has led to a decline in the valuation of public genomic medicine companies. The potential of genomic medicines and the associated market size remain uncertain, posing questions for pharma companies and investors.